Cardinal Health Inc. (CAH) is well-poised for growth, given its long-term supply agreements, diversified product portfolio and strong quarterly earnings. However, the possibility of losing a major customer remains a risk.Shares of this Zacks Rank #2 (Buy) company have risen 12.7% in the past year compared with the industry’s 1.5% growth. The S&P 500 Index has gained 26.2% in the same time frame. CAH, with a market capitalization of $28.62 billion, is a nationwide drug distributor and service provider to pha ...

Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarkets.com's offering.The "Canada Personal Protective Equipment Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Canada Personal Protective Equipment market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Examination ...

The most recent trading session ended with Cardinal Health (CAH) standing at $118.83, reflecting a +0.41% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 1.1%. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.35%.Shares of the prescription drug distributor have depreciated by 2.81% over the course of the past month, outperforming the Medical sector's loss of 3.78% and lagging the S&P 500's gain of 0.22%.Investors will be eagerly watchi ...

DUBLIN, Ohio, Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are underva ...

Core Viewpoint - Cardinal Health Inc. is positioned for growth through an acquisition-driven strategy, a diversified product portfolio, and a strong pharmaceutical segment, despite facing inflationary pressures [1][2]. Financial Performance - Cardinal Health's shares have increased by 24.3% year-to-date, outperforming the industry gain of 4.8% and the S&P 500 Index's increase of 27.1% [1]. - The company has a market capitalization of $29.83 billion and an earnings yield of 6.3%, higher than the industry's 4.6% [2]. - Cardinal Health anticipates a 10.2% improvement in earnings over the next five years [2]. Pharmaceutical Segment Insights - The pharmaceutical segment is a key growth driver, with products and services including pharmaceutical distribution and specialty services [4]. - In Q4 fiscal 2024, total revenues declined by 4.3% year-over-year to $52.28 billion, with pharmaceutical revenues decreasing by 5% to $48 billion. Excluding the OptumRx impact, pharmaceutical sales increased by 16% [5]. - The company expects a 4-6% decline in pharmaceutical revenues for fiscal 2025, primarily due to the OptumRx contract expiration, which represents a $39 billion revenue headwind [6]. Recent Acquisitions - Cardinal Health has recently acquired Advanced Diabetes Supply Group and a majority stake in GI Alliance, which are expected to enhance revenues and profits in the first 12 months post-acquisition [6][8]. - These acquisitions align with Cardinal Health's strategy to support the growing diabetic patient population and expand its multi-specialty platform [7]. Q1 Fiscal 2024 Results - The company reported strong Q1 results, with global medical products and distribution revenues totaling $3.1 billion, a 3% year-over-year increase [10]. - Gross profit rose by 9.1% year-over-year, and operating income improved significantly to $568 million from an operating loss of $32 million in the previous year [11]. Notable Developments - Cardinal Health launched the Kendall SCD SmartFlow Compression System, aimed at preventing venous thromboembolism and enhancing patient care [12]. - The company entered a multi-year exclusive agreement with T2 Biosystems to distribute rapid diagnostics for sepsis detection [13]. Revenue Estimates - The Zacks Consensus Estimate for fiscal 2025 revenues is $219 billion, indicating a 3.5% decline from the previous year, while adjusted earnings per share are expected to increase by 3.9% to $7.82 [17].

Summary of Cardinal Health, Inc. Conference Call Company Overview - **Company**: Cardinal Health, Inc. (NYSE: CAH) - **Event**: Citi's 2024 Global Healthcare Conference Call - **Date**: December 3, 2024 - **Participants**: - Aaron Alt - Chief Financial Officer - Matt Sims - Head of Investor Relations - Daniel Grosslight - Citi Health Tech and Distribution Analyst Key Points Discussed Industry and Political Environment - **Impact of New Administration**: Discussion on how the new administration may affect Cardinal Health's business, particularly regarding tariffs and healthcare policies [2] - **Tariffs Concerns**: Focus on potential tariffs not only from China but also on Mexico, Canada, and BRICS nations, indicating a broader geopolitical concern that could impact supply chains and costs [2] Financial and Operational Insights - **CFO's Remarks**: Aaron Alt indicated that there would be comments on political and forward-looking aspects after initial remarks from Matt Sims, suggesting a structured approach to addressing concerns [3] Additional Notes - **Conference Context**: The call is positioned within a broader healthcare conference, indicating the importance of industry dynamics and investor relations in the current market environment [1] - **Engagement with Analysts**: The format of the call allows for direct engagement with analysts, highlighting the company's transparency and willingness to discuss sensitive topics such as politics and tariffs [2][4]

Group 1 - Cardinal Health participated in Citi's 2024 Global Healthcare Conference, with CFO Aaron Alt and Head of Investor Relations Matt Sims representing the company [1] - The discussion included the potential impact of the new administration on the healthcare sector, particularly regarding tariffs on imports from countries like China, Mexico, Canada, and BRICS nations [2] - The conversation was initiated by Daniel Grosslight, a health tech and distribution analyst at Citi, highlighting the significance of political changes on business operations [2]

Cardinal Health (CAH) recently launched the Kendall SCD SmartFlow Compression System in the United States. The system is the next generation of the Kendall Compression Series, offering an enhanced clinician and patient experience.Kendall SCD SmartFlow Compression System is designed to help prevent venous thromboembolism events, enhance blood circulation and treat pain and swelling related to venous stasis.Likely Trend of CAH Stock Following the NewsFollowing the announcement, shares of the company moved mov ...

Group 1 - Cardinal Health participated in the UBS Global Healthcare Conference on November 12, 2024, with key management including CFO Aaron Alt and VP of Investor Relations Matt Sims [1][2] - The company announced two significant deals prior to the conference, which prompted a change in the planned discussion topics [3][4] - The management expressed enthusiasm about the strategic initiatives associated with the newly announced deals, indicating a proactive approach to engaging with investors [3]